Aztreonam

The dosage of Aztreonam is determined by the healthcare provider based on the severity of the infection, the site of the infection, and the patient's renal function. According to the FDA-approved prescribing information, the standard adult dosages are as follows:

• Urinary Tract Infections: 500 mg or 1 gram administered every 8 or 12 hours.
• Moderately Severe Systemic Infections: 1 gram or 2 grams administered every 8 or 12 hours.
• Severe or Life-Threatening Infections: 2 grams administered every 6 or 8 hours. The maximum recommended dose is 8 grams per day.
• Inhalation for Cystic Fibrosis: The typical dose is 75 mg administered three times daily for a 28-day cycle, followed by 28 days off the medication.

For intramuscular (IM) administration, doses greater than 1 gram are generally not recommended; instead, the intravenous (IV) route should be used for higher doses.

Aztreonam is approved for use in pediatric patients for the treatment of various Gram-negative infections. The dosage is typically calculated based on the child's body weight:

• Infants and Children (>1 month old): The standard dose is 30 mg/kg administered every 6 or 8 hours. For very severe infections in children older than 2 years, doses up to 50 mg/kg every 6 hours may be used, not to exceed the maximum adult dose of 8 grams per day.
• Neonates (<1 month old): Dosing in newborns is specialized and depends on gestational age and birth weight. Healthcare providers typically use 30 mg/kg every 8 to 12 hours.

Renal Impairment

Because Aztreonam is primarily cleared by the kidneys, dosage adjustments are critical for patients with reduced renal function to prevent drug accumulation and toxicity.

• Creatinine Clearance (CrCl) 10-30 mL/min: After an initial loading dose of 1 or 2 grams, the maintenance dose is typically reduced by 50%.
• CrCl <10 mL/min (including dialysis patients): After the loading dose, the maintenance dose is typically reduced to 25% of the standard dose. For patients on hemodialysis, a supplemental dose (1/8 of the initial dose) may be given after each dialysis session.

Hepatic Impairment

While Aztreonam is not extensively metabolized by the liver, patients with severe hepatic impairment should be monitored closely. However, standard labeling does not currently mandate specific dosage reductions for liver disease alone, as renal clearance remains the primary elimination pathway.

Elderly Patients

Older adults are more likely to have decreased renal function. Healthcare providers should assess the glomerular filtration rate (GFR) in elderly patients and adjust the dose of Aztreonam accordingly. Monitoring kidney function throughout therapy is highly recommended in this population.

Aztreonam is administered by healthcare professionals in a clinical setting via injection or infusion.

• Intravenous (IV) Infusion: The drug is usually infused over a period of 20 to 60 minutes. It can also be given as a slow IV bolus (injection) over 3 to 5 minutes.
• Intramuscular (IM) Injection: The injection should be made deep into a large muscle mass (such as the gluteus maximus).
• Inhalation: If using the inhaled form (Cayston), it must be used only with the Altera Nebulizer System. Patients are usually instructed to use a bronchodilator before the Aztreonam dose to open the airways.
• Storage: Reconstituted solutions for injection should be used promptly. If stored at room temperature, they are generally stable for 24 hours; if refrigerated, they may last up to 7 days, depending on the diluent used.

In a hospital setting, your nursing staff will manage your dosing schedule. If you are using the inhaled version at home and miss a dose, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up.

An overdose of Aztreonam is rare since it is usually administered by medical professionals. However, symptoms of overdose may include an exacerbation of side effects or seizures. In the event of a suspected overdose, emergency measures include supportive care and, if necessary, hemodialysis or peritoneal dialysis to help remove the drug from the bloodstream.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication early without medical guidance, as this can lead to antibiotic resistance.

Aztreonam is generally well-tolerated, but like all antibiotics, it can cause side effects. The most frequently reported adverse reactions occur at the site of administration:

• Injection Site Reactions: Approximately 2% to 10% of patients experience localized pain, redness, or swelling at the IV or IM injection site. This is usually transient and resolves shortly after the infusion is complete.
• Gastrointestinal Distress: Mild diarrhea, nausea, and vomiting are common. These symptoms occur as the antibiotic alters the balance of bacteria in the gut. They typically last only as long as the treatment duration.
• Dermatologic Reactions: A mild skin rash or itching (pruritus) may occur. If the rash is mild and not accompanied by swelling or difficulty breathing, it may not require discontinuation of the drug, but it must be reported to a doctor.

• Phlebitis/Thrombophlebitis: Inflammation of the vein used for IV administration can occur, sometimes leading to a small blood clot in the vein. This may feel like a hard, tender cord under the skin.
• Fever: Some patients may develop a 'drug fever' shortly after administration, which subsides once the drug is discontinued.
• Vaginitis: Yeast infections or vaginal discharge may occur due to the disruption of normal vaginal flora.

• Hepatotoxicity: Rare elevations in liver enzymes (ALT, AST) and alkaline phosphatase have been observed. In very rare cases, jaundice or hepatitis may occur.
• Hematologic Changes: Some patients may experience a temporary decrease in white blood cells (neutropenia), a decrease in platelets (thrombocytopenia), or an increase in eosinophils (eosinophilia).
• Neurological Effects: Rarely, patients have reported confusion, seizures, or dizziness, particularly those with pre-existing renal impairment who received high doses.

> Warning: Stop taking Aztreonam and call your doctor immediately or seek emergency care if you experience any of the following:

1. 1Anaphylaxis (Severe Allergic Reaction): Symptoms include hives, swelling of the face, lips, or tongue, difficulty breathing, wheezing, and a rapid drop in blood pressure (fainting). Although Aztreonam is often safe for those with penicillin allergies, severe reactions can still occur.
2. 2Clostridioides difficile-Associated Diarrhea (CDAD): This is a severe form of diarrhea caused by an overgrowth of C. diff bacteria. Symptoms include watery or bloody stools, severe stomach cramps, and fever. This can occur during treatment or even weeks after stopping the antibiotic.
3. 3Toxic Epidermal Necrolysis (TEN) or Stevens-Johnson Syndrome (SJS): These are life-threatening skin reactions. Seek help if you develop a painful red or purplish rash that spreads and causes blistering and peeling of the skin or mucous membranes.
4. 4Seizures: Especially in patients with kidney disease, high levels of the drug can trigger neurological irritability.

Aztreonam is typically used for short-term acute infections (7 to 14 days). Long-term use is generally limited to the inhaled form for cystic fibrosis. Prolonged or repeated use of any antibiotic can lead to:

• Superinfection: The overgrowth of non-susceptible organisms, such as fungi (Candida) or resistant bacteria, which may require separate treatment.
• Development of Resistance: Using the drug longer than necessary or for inappropriate reasons can contribute to the development of multi-drug resistant 'superbugs.'

Currently, there are no FDA Black Box Warnings for Aztreonam. However, this does not mean the drug is without risk. The most significant warnings in the official labeling concern the risk of hypersensitivity and the potential for C. diff infections.

Report any unusual symptoms or persistent side effects to your healthcare provider immediately. Adverse events can also be reported to the FDA at 1-800-FDA-1088.

Aztreonam should only be used to treat infections that are proven or strongly suspected to be caused by susceptible Gram-negative bacteria. Using it for viral infections (like the common cold) or Gram-positive infections will not be effective and increases the risk of antibiotic resistance. Patients must complete the full course of therapy even if they feel better after the first few doses.

No FDA black box warnings for Aztreonam.

• Allergic Reactions / Anaphylaxis Risk: Before starting Aztreonam, your doctor must know if you have ever had an allergic reaction to penicillins, cephalosporins, or carbapenems. While Aztreonam is structurally different and often safe for these patients, cross-reactivity has been reported, particularly with the cephalosporin antibiotic Ceftazidime, which shares a similar side chain. If an allergic reaction occurs, the drug must be stopped immediately and emergency treatment (epinephrine, oxygen, IV fluids) initiated.
• Clostridioides difficile-Associated Diarrhea (CDAD): Treatment with Aztreonam alters the normal flora of the colon, which may permit overgrowth of C. difficile. This can range in severity from mild diarrhea to fatal colitis. If you experience persistent diarrhea, do not take anti-diarrheal medications (like loperamide) without consulting your doctor, as these can make the condition worse.
• Renal Function Monitoring: Because the drug is excreted by the kidneys, patients with known or suspected renal impairment require frequent monitoring. High serum levels in these patients can lead to central nervous system toxicity, including seizures.
• Superinfection: As with other antibiotics, use of Aztreonam may result in overgrowth of non-susceptible organisms, including Gram-positive cocci (like Staphylococcus) and fungi. If a superinfection occurs during therapy, appropriate measures should be taken.

Healthcare providers will typically order the following tests while a patient is receiving Aztreonam, especially for prolonged courses (longer than 10 days):

• Renal Function Tests: Serum creatinine and Blood Urea Nitrogen (BUN) to ensure the kidneys are clearing the drug effectively.
• Liver Function Tests (LFTs): To monitor for rare elevations in liver enzymes.
• Complete Blood Count (CBC): To monitor for rare hematologic changes like neutropenia or thrombocytopenia.

Aztreonam is not known to significantly impair the ability to drive or operate machinery. However, if you experience rare side effects like dizziness or confusion, you should avoid these activities until the symptoms resolve.

There is no specific contraindication between Aztreonam and alcohol. However, alcohol can dehydrate the body and strain the liver and kidneys, which are already working to process the infection and the medication. It is generally advisable to avoid alcohol while fighting a serious infection to allow the immune system to function optimally.

Unlike some medications (such as steroids or antidepressants), Aztreonam does not require a tapering period. However, it is vital NOT to stop the medication early just because symptoms improve. Premature discontinuation allows the strongest bacteria to survive, potentially leading to a relapse of an even more resistant infection.

> Important: Discuss all your medical conditions, especially kidney disease and previous antibiotic allergies, with your healthcare provider before starting Aztreonam.

There are no absolute drug-drug contraindications where Aztreonam must never be used with another agent. However, certain combinations are avoided unless absolutely necessary due to predictable risks.

• Aminoglycosides (e.g., Gentamicin, Amikacin): These are often used in combination with Aztreonam for a synergistic effect against Pseudomonas aeruginosa. While effective, this combination increases the risk of nephrotoxicity (kidney damage) and ototoxicity (hearing loss). Renal function and hearing should be monitored closely.
• Cefazolin and Other Cephalosporins: Some studies suggest that using high doses of cephalosporins alongside other beta-lactams might increase the risk of kidney strain. Monitoring of renal parameters is advised.
• Oral Anticoagulants (e.g., Warfarin): Like many antibiotics, Aztreonam can alter the gut flora that produces Vitamin K. This may enhance the effect of Warfarin, leading to an increased risk of bleeding. Healthcare providers typically monitor the International Normalized Ratio (INR) more frequently when starting or stopping Aztreonam.

• Probenecid: This medication, used for gout, inhibits the renal tubular secretion of Aztreonam. This can lead to higher and more prolonged serum levels of Aztreonam. While not usually dangerous, it may increase the risk of side effects.
• Furosemide (Lasix): High doses of potent diuretics can affect renal clearance. While no major clinical consequence is usually seen, monitoring kidney function is prudent.

Since Aztreonam is administered by injection or inhalation, food does not affect its absorption or efficacy. There are no known restrictions regarding grapefruit, dairy, or high-fat meals.

• Probiotics: While many patients take probiotics to prevent antibiotic-associated diarrhea, the antibiotic may kill the beneficial bacteria in the supplement. It is often recommended to space the probiotic dose at least 2 hours away from the antibiotic administration.
• Vitamin K Supplements: Because Aztreonam can lower Vitamin K levels produced by gut bacteria, taking large amounts of Vitamin K supplements might interfere with the intended 'blood thinning' effects if you are also on Warfarin. Always consult your doctor before starting supplements.

• Coombs' Test: Aztreonam may cause a false-positive result in the direct Coombs' test (a test for hemolytic anemia).
• Urinary Glucose: Like some other beta-lactams, Aztreonam may cause false-positive results for glucose in the urine when using copper reduction tests (e.g., Benedict's solution or Clinitest). It does not affect glucose oxidase-based tests (e.g., Clinistix).
• Prothrombin Time: As mentioned, Aztreonam can prolong PT/INR in patients on anticoagulants.

For each interaction, the management strategy involves clinical monitoring and potential dose adjustment of the interacting agent.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter drugs.

Aztreonam is strictly contraindicated in patients with a known hypersensitivity to Aztreonam or any component of the formulation. An absolute contraindication means the drug should never be used because the risk of a life-threatening reaction far outweighs any potential benefit.

• Mechanism: In sensitized individuals, the immune system recognizes the aztreonam molecule as a foreign invader, triggering a massive release of histamine and other inflammatory mediators. This can lead to anaphylactic shock, airway obstruction, and death.

Relative contraindications are conditions where the drug should be used with extreme caution and only if the benefits clearly justify the risks:

• Severe Penicillin or Cephalosporin Allergy: While Aztreonam is often used as a safe alternative for these patients, those with a history of anaphylactic reactions to other beta-lactams should be monitored with extreme care during the first dose, as rare cross-reactivity can occur.
• Pre-existing Seizure Disorders: Because beta-lactams can lower the seizure threshold, especially in the presence of renal impairment, patients with epilepsy should be monitored closely.
• Severe Renal Impairment (CrCl < 10 mL/min): While not a reason to withhold the drug if it is the only effective option, it requires drastic dose reductions and intensive monitoring to avoid toxicity.

A specific concern exists regarding Ceftazidime. Aztreonam and Ceftazidime share an identical side chain at the 3-position of the beta-lactam ring. Clinical data suggest that patients who are specifically allergic to Ceftazidime are at a much higher risk of being allergic to Aztreonam compared to those allergic to other penicillins. If you have had a reaction to Ceftazidime, ensure your healthcare provider is aware before receiving Aztreonam.

> Important: Your healthcare provider will evaluate your complete medical history and previous antibiotic reactions before prescribing Aztreonam.

Aztreonam is classified as FDA Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.

• Trimester-Specific Risks: Data from animal studies (rats and rabbits) using doses up to 15 times the human dose showed no evidence of embryotoxicity or teratogenicity (birth defects).
• Clinical Use: Aztreonam should be used during pregnancy only if clearly needed. Healthcare providers typically weigh the severity of the maternal infection against the theoretical risk to the fetus. It is generally considered one of the safer options for serious Gram-negative infections in pregnant patients when other first-line agents are inappropriate.

Aztreonam is excreted in human breast milk in very low concentrations (less than 1% of the maternal serum concentration).

• Known Effects: The risk to the nursing infant is considered low. However, potential effects include alteration of the infant's gut flora (leading to diarrhea or thrush) or the rare possibility of allergic sensitization.
• Recommendation: The American Academy of Pediatrics considers Aztreonam to be generally compatible with breastfeeding. Nevertheless, nursing mothers should monitor their infants for diarrhea or diaper rash.

Aztreonam is approved for use in pediatric patients, including neonates.

• Safety: The safety and effectiveness of the IV/IM form have been established for infants as young as 1 month old. For the inhaled form (Cayston), safety has only been established in children 7 years of age and older.
• Special Considerations: In neonates, the half-life of the drug is prolonged due to immature renal function, requiring longer dosing intervals (e.g., every 12 hours instead of every 8).

Clinical studies of Aztreonam did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects.

• Renal Concerns: The most significant concern in the elderly is the natural age-related decline in renal function. Since Aztreonam is renally excreted, the risk of toxic reactions is greater in those with impaired kidney function.
• Dosing: Healthcare providers should choose the dose carefully, often starting at the lower end of the dosing range, and monitor renal function (creatinine clearance) throughout therapy.

Patients with a GFR (Glomerular Filtration Rate) below 30 mL/min require significant dose adjustments. In patients with end-stage renal disease (ESRD) on hemodialysis, the drug is cleared at a rate of about 20-50 mL/min. A supplemental dose is often required after dialysis to maintain therapeutic levels.

In patients with liver cirrhosis, the half-life of Aztreonam is slightly prolonged (by about 20-25%), but the kidneys usually compensate for this. Most patients with hepatic impairment do not require a dose adjustment unless concurrent renal failure is present (hepatorenal syndrome).

> Important: Special populations require individualized medical assessment and frequent monitoring by a clinical team.

Aztreonam is a bactericidal antibiotic that acts by inhibiting bacterial cell wall synthesis. Its molecular target is Penicillin-Binding Protein 3 (PBP3), an enzyme located on the inner membrane of Gram-negative bacteria. By covalently binding to the active site of PBP3, Aztreonam prevents the cross-linking of peptidoglycan chains. This results in the inhibition of septum formation during bacterial cell division, leading to filamentation and eventual osmotic lysis of the cell. Its unique monobactam structure makes it highly resistant to many beta-lactamases, including metallo-beta-lactamases, though it remains vulnerable to certain ESBLs.

The efficacy of Aztreonam is time-dependent. This means that the clinical outcome is best predicted by the amount of time the concentration of the drug in the blood remains above the Minimum Inhibitory Concentration (MIC) of the target bacteria (T > MIC). For optimal killing, the drug concentration should exceed the MIC for at least 40-60% of the dosing interval. There is a minimal post-antibiotic effect (PAE) against Gram-negative bacilli, meaning the drug stops working quickly once levels drop below the MIC.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV/IM) |

| Protein Binding | 56% to 60% |

| Half-life | 1.7 - 2.0 hours (Adults) |

| Tmax | 0.6 - 1.3 hours (IM) |

| Metabolism | Minimal (approx. 6-16% to inactive metabolites) |

| Excretion | Renal 60-70%; Fecal approx. 12% |

• Molecular Formula: C13H17N5O8S2
• Molecular Weight: 435.43 g/mol
• Solubility: Soluble in water; slightly soluble in methanol.
• Structure: It consists of a sulfonic acid group attached to the nitrogen of the beta-lactam ring, and an aminothiazole oxime side chain which provides its Gram-negative specificity.

Aztreonam belongs to the Monobactam class of antibacterials. It is currently the only FDA-approved drug in this class. It is often grouped with other beta-lactams but is unique because it does not have the secondary ring structure found in penicillins (thiazolidine ring) or cephalosporins (dihydrothiazine ring).